Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : U.S. FDA approves Takeda's lung cancer therapy

09/15/2021 | 05:42pm EDT

Sept 15 (Reuters) - Japanese pharma company Takeda Pharmaceutical Co said on Wednesday the U.S. Food and Drug Administration approved its drug, Exkivity, to treat a type of lung cancer.

Takeda said the approval was based on an early-to-mid-stage trial testing 114 patients with non-small cell lung cancer, with results showing clinically meaningful responses with a median duration of about 18 months.

Exkivity was approved for patients with a specific gene mutation called EGFR Exon20 insertions in non-small cell lung cancer, whose disease has progressed on or after chemotherapy.

The company said the approval for the indication was contingent upon verification and description of clinical benefit in a confirmatory trial.

Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of the estimated 2.2 million new cases of lung cancer diagnosed each year worldwide, according to the World Health Organization.

The drug comes with a boxed warning flagging risks of potential heart toxicity, lung disease and heart rhythm disturbances.

(Reporting by Dania Nadeem in Bengaluru; Editing by Shailesh Kuber and Krishna Chandra Eluri)


© Reuters 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10:28aNOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10:23aNOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18CALITHERA BIOSCIENCES : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipel..
MT
10/18Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from ..
CI
10/18Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma
DJ
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
BU
10/13Immusoft and Takeda Pharmaceutical Company Limited Collaborate to Discover and Develop ..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 391 B 29 675 M 29 675 M
Net income 2022 248 B 2 170 M 2 170 M
Net Debt 2022 3 258 B 28 510 M 28 510 M
P/E ratio 2022 20,8x
Yield 2022 5,55%
Capitalization 5 104 B 44 688 M 44 674 M
EV / Sales 2022 2,47x
EV / Sales 2023 2,33x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 246,00 JPY
Average target price 4 487,14 JPY
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.56%43 985
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674